Abstract
Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse-effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant English-language literature was identified through searches of NCI, PubMed, ASCO.org and ESMO, ECCO meetings proceedings.
MeSH terms
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bile Duct Neoplasms / drug therapy
-
Bile Ducts, Extrahepatic
-
Camptothecin / analogs & derivatives
-
Camptothecin / therapeutic use
-
Capecitabine
-
Chemotherapy, Adjuvant
-
Cholangiocarcinoma / drug therapy
-
Colonic Neoplasms / drug therapy
-
Colonic Neoplasms / pathology
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Digestive System Neoplasms / drug therapy*
-
Docetaxel
-
Esophageal Neoplasms / drug therapy
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives*
-
Fluorouracil / therapeutic use
-
Gallbladder Neoplasms / drug therapy
-
Humans
-
Irinotecan
-
Liver Neoplasms / secondary
-
Organoplatinum Compounds / administration & dosage
-
Oxaliplatin
-
Pancreatic Neoplasms / drug therapy
-
Rectal Neoplasms / drug therapy
-
Rectal Neoplasms / pathology
-
Stomach Neoplasms / drug therapy
-
Taxoids / administration & dosage
-
Treatment Outcome
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Antimetabolites, Antineoplastic
-
Organoplatinum Compounds
-
Taxoids
-
Vascular Endothelial Growth Factor A
-
Oxaliplatin
-
Deoxycytidine
-
Docetaxel
-
Capecitabine
-
Irinotecan
-
Fluorouracil
-
Camptothecin